Home › Myelodysplastic Syndromes › Kentucky
Myelodysplastic Syndromes clinical trials in Kentucky
5 studies for Myelodysplastic Syndromes are looking for participants at sites in Kentucky.
Cities in Kentucky
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- University of Kentucky/Markey Cancer Center, Lexington
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05564390Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06577441A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Norton Cancer Institute, Louisville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07422480The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- University of Kentucky/Markey Cancer Center, Lexington
- Norton Children's Hospital, Louisville
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Norton Cancer Institute, Louisville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT06499285From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.